Autolus Therapeutics

Today we announced operational and financial results for year-end 2024. It was a year of strong execution leading to significant achievements for Autolus, including our strategic deal with BioNTech and corresponding financing to bolster our balance sheet, commencing GMP operations at our in-house CAR T manufacturing facility, and finishing the year with our first FDA approval and commercial launch. To access a live webcast of our earnings conference call at 8:30am ET / 12:30pm GMT, please visit: https://lnkd.in/eYcZv3Yn

For Investors and Analysts Today we announced a business update and an overview of our 2025 anticipated milestones. We are looking forward to a busy and productive J.P. Morgan Healthcare Conference! https://lnkd.in/eisVFNzk

Congratulations to Autolus Therapeutics' Chief Scientific Officer and Founder, Dr. Martin Pule, authors Dr. Claire Roddie and Dr. Elias Jabbour and team, on the publication of the FELIX Phase 1b/2 trial in the prestigious, peer-reviewed scientific journal, The New England Journal of Medicine https://lnkd.in/dDXebU7W

At Autolus, we believe that diverse experiences fuel innovation and progress. That's why we welcome individuals from all backgrounds and experience levels to join our passionate team. Our comprehensive training programs are designed to empower everyone, from newcomers to seasoned professionals, ensuring that you have the skills and knowledge needed to thrive. We are committed to fostering an inclusive environment where every voice is heard and valued. Together, we’re not just advancing science; we’re making a meaningful difference in patients' lives. Join us and be part of a team that champions growth, inclusivity, and impact! To learn more about this initiative click below:? https://lnkd.in/d8-z8rB

A great evening at the European Lifestars Awards last night and thrilled to have won the award for Deal of the Year (< EUR500m) - which was accepted by Chris Williams and Melanie Georgiou.

For Investors & Analysts: ? BREAKING NEWS: The U.S. Food and Drug Administration (FDA) has approved Autolus Therapeutics' first CAR T cell therapy product. Read more here: https://lnkd.in/eRXseAVk

Autolus is delighted to announce that we have been awarded Silver on the Inclusive Employers Standard. The Inclusive Employers Standard is a robust evidence-based accreditation run by Inclusive Employers. We are very proud of this achievement, which has energised us to continue our inclusion development and enhance the positive impact of inclusion both within our organisation and the wider industry.

For Investors and Analysts Autolus is proud to announce that the company has reached its 10-year milestone:

For Investors and Analysts Autolus Therapeutics is delighted to announce the appointment of Dr Matthias Will as Chief Development Officer. Dr Will joins Autolus on September 30. Welcome to the team! Read more here: https://lnkd.in/eD8ef6rD

Autolus is delighted to announce some recent promotions that recognize each individuals significant leadership experience. Andrea Braun-Scherhag, Markus Gruell, Claudia Mercedes Mayer, Chris Gray, Dilip P.